Abstract
With the increasing global human population, travel, and socioeconomic activities, more and more novel pathogenic viruses will emerge or re-emerge. While more than 260 viruses are known to infect humans, only a small minority of these viral diseases are treatable by clinically approved antiviral drugs. Apart from these identified viruses, new emerging viruses and drug-resistant viruses are also important challenges to our public health and healthcare systems. The COVID-19 and influenza pandemics remind us the importance of getting broad-spectrum antivirals against emerging and re-emerging respiratory viruses. Broad-spectrum antivirals against different viral families for fighting the currently known viruses and novel emerging viruses are urgently needed. Viral entry is the universal first step for viral infection, and therefore is a promising target for identifying broad-spectrum antivirals. In this chapter, we mainly focus on discussing the risks of respiratory viruses, the challenge of finding broad-spectrum antivirals, the entry processes of respiratory viruses, the current studies on broad-spectrum entry inhibitors for respiratory viruses, and the directions for discovering broad-spectrum antivirals in the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anthony SJ, Epstein JH, Murray KA, Navarrete-Macias I, Zambrana-Torrelio CM, Solovyov A, Ojeda-Flores R, Arrigo NC, Islam A, Ali Khan S, Hosseini P, Bogich TL, Olival KJ, Sanchez-Leon MD, Karesh WB, Goldstein T, Luby SP, Morse SS, Mazet JA, Daszak P, Lipkin WI (2013) A strategy to estimate unknown viral diversity in mammals. MBio 4:e00598–e00513. https://doi.org/10.1128/mBio.00598-13
Armero A, Berthet N, Avarre JC (2021) Intra-host diversity of SARS-Cov-2 should not be neglected: case of the state of Victoria, Australia. Viruses 13:133. https://doi.org/10.3390/v13010133
Arnberg N, Pring-Akerblom P, Wadell G (2002) Adenovirus type 37 uses sialic acid as a cellular receptor on Chang C cells. J Virol 76:8834–8841. https://doi.org/10.1128/jvi.76.17.8834-8841.2002
Arora P, Pöhlmann S, Hoffmann M (2021) Mutation D614G increases SARS-CoV-2 transmission. Signal Transduct Target Ther 6:101. https://doi.org/10.1038/s41392-021-00502-w
Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, Penn R, Jimenez-Guardeño JM, Ortega-Prieto AM, Bussani R, Cannatà A, Rizzari G, Collesi C, Schneider E, Arosio D, Shah AM, Barclay WS, Malim MH, Burrone J, Giacca M (2021) Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia. Nature 594:88. https://doi.org/10.1038/s41586-021-03491-6
Brice DC, Diamond G (2020) Antiviral activities of human host defense peptides. Curr Med Chem 27:1420–1443. https://doi.org/10.2174/0929867326666190805151654
Chan RW, Chan MC, Wong AC, Karamanska R, Dell A, Haslam SM, Sihoe AD, Chui WH, Triana-Baltzer G, Li Q, Peiris JS, Fang F, Nicholls JM (2009) DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 53:3935–3941. https://doi.org/10.1128/aac.00389-09
Chaudhuri S, Symons JA, Deval J (2018) Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antivir Res 155:76–88. https://doi.org/10.1016/j.antiviral.2018.05.005
Chemaly RF, Marty FM, Wolfe CR, Lawrence SJ, Dadwal S, Soave R, Farthing J, Hawley S, Montanez P, Hwang J, Ho J, Lewis S, Wang G, Boeckh M (2021) DAS181 treatment of severe lower respiratory tract parainfluenza virus infection in immunocompromised patients: a phase 2 randomized, placebo-controlled study. Clin Infect Dis 73:e773. https://doi.org/10.1093/cid/ciab113
Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV (2008) A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 105:3088–3093. https://doi.org/10.1073/pnas.0712380105
Chibanga VP, Dirr L, Guillon P, El-Deeb IM, Bailly B, Thomson RJ, von Itzstein M (2019) New antiviral approaches for human parainfluenza: inhibiting the haemagglutinin-neuraminidase. Antivir Res 167:89–97. https://doi.org/10.1016/j.antiviral.2019.04.001
Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz SA, Kwong EM, McVicar RN, Thacker BE, Glass CA, Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garretson AF, Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kellman BP, Martino C, Gordts P, Chanda SK, Schmidt AG, Godula K, Leibel SL, Jose J, Corbett KD, Ward AB, Carlin AF, Esko JD (2020) SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183:1043–1057.e1015. https://doi.org/10.1016/j.cell.2020.09.033
Das K, Aramini JM, Ma LC, Krug RM, Arnold E (2010) Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 17:530–538. https://doi.org/10.1038/nsmb.1779
Das DK, Bulow U, Diehl WE, Durham ND, Senjobe F, Chandran K, Luban J, Munro JB (2020) Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. PLoS Biol 18:e3000626. https://doi.org/10.1371/journal.pbio.3000626
Donalisio M, Rusnati M, Civra A, Bugatti A, Allemand D, Pirri G, Giuliani A, Landolfo S, Lembo D (2010) Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob Agents Chemother 54:4290–4299. https://doi.org/10.1128/aac.00471-10
Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol 7:226–236. https://doi.org/10.1038/nrmicro2090
Ekins S, Lane TR, Madrid PB (2020) Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond. Pharm Res 37:71. https://doi.org/10.1007/s11095-020-02799-8
Elahi S, Niki T, Hirashima M, Horton H (2012) Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood 119:4192–4204. https://doi.org/10.1182/blood-2011-11-389585
Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H (2015) Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis 21:1065–1067. https://doi.org/10.3201/eid2106.150176
Fukushima K, Takahashi T, Ito S, Takaguchi M, Takano M, Kurebayashi Y, Oishi K, Minami A, Kato T, Park EY, Nishimura H, Takimoto T, Suzuki T (2014) Terminal sialic acid linkages determine different cell infectivities of human parainfluenza virus type 1 and type 3. Virology 464-465:424–431. https://doi.org/10.1016/j.virol.2014.07.033
Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, Robertson JS, Bovin NV, Matrosovich MN (1997) Specification of receptor-binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6′-sialyl(N-acetyllactosamine). Virology 232:345–350. https://doi.org/10.1006/viro.1997.8572
Gambaryan AS, Boravleva EY, Matrosovich TY, Matrosovich MN, Klenk HD, Moiseeva EV, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV (2005) Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by influenza virus. Antivir Res 68:116–123. https://doi.org/10.1016/j.antiviral.2005.07.008
Gillespie EJ, Ho CL, Balaji K, Clemens DL, Deng G, Wang YE, Elsaesser HJ, Tamilselvam B, Gargi A, Dixon SD, France B, Chamberlain BT, Blanke SR, Cheng G, de la Torre JC, Brooks DG, Jung ME, Colicelli J, Damoiseaux R, Bradley KA (2013) Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A 110:E4904–E4912. https://doi.org/10.1073/pnas.1302334110
Greber UF, Flatt JW (2019) Adenovirus entry: from infection to immunity. Annu Rev Virol 6:177–197. https://doi.org/10.1146/annurev-virology-092818-015550
Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A (2000) The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J Virol 74:11108–11114. https://doi.org/10.1128/jvi.74.23.11108-11114.2000
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A (2018) Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379:913–923. https://doi.org/10.1056/nejmoa1716197
Heida R, Bhide YC, Gasbarri M, Kocabiyik Ö, Stellacci F, Huckriede ALW, Hinrichs WLJ, Frijlink HW (2021) Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discov Today 26:122–137. https://doi.org/10.1016/j.drudis.2020.10.009
Hoffmann HH, Palese P, Shaw ML (2008) Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antivir Res 80:124–134. https://doi.org/10.1016/j.antiviral.2008.05.008
Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N, Graichen L, Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, Jäck HM, Jahrsdörfer B, Schrezenmeier H, Müller M, Kleger A, Münch J, Pöhlmann S (2021) SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184:2384–2393.e2312. https://doi.org/10.1016/j.cell.2021.03.036
Hollmann A, Castanho MA, Lee B, Santos NC (2014) Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors. Biochem J 459:161–170. https://doi.org/10.1042/bj20131058
Holthuis JC, Levine TP (2005) Lipid traffic: floppy drives and a superhighway. Nat Rev Mol Cell Biol 6:209–220. https://doi.org/10.1038/nrm1591
Hörnich BF, Großkopf AK, Schlagowski S, Tenbusch M, Kleine-Weber H, Neipel F, Stahl-Hennig C, Hahn AS (2021) SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation. J Virol 95:e00002. https://doi.org/10.1128/jvi.00002-21
Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM (2019) Arbidol and other low-molecular-weight drugs that inhibit lassa and ebola viruses. J Virol 93:e02185. https://doi.org/10.1128/jvi.02185-18
Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T (2020) Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med 383:309–320. https://doi.org/10.1056/nejmoa1915341
Jary A, Leducq V, Malet I, Marot S, Klement-Frutos E, Teyssou E, Soulié C, Abdi B, Wirden M, Pourcher V, Caumes E, Calvez V, Burrel S, Marcelin AG, Boutolleau D (2020) Evolution of viral quasispecies during SARS-CoV-2 infection. Clin Microbiol Infect 26:1560.e1561–1560.e1564
Jiang S, Lin K, Strick N, Neurath AR (1993) HIV-1 inhibition by a peptide. Nature 365:113. https://doi.org/10.1016/j.cmi.2020.07.032
Kadam RU, Wilson IA (2017) Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A 114:206–214. https://doi.org/10.1073/pnas.1617020114
Kamhi E, Joo EJ, Dordick JS, Linhardt RJ (2013) Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc 88:928–943. https://doi.org/10.1111/brv.12034
Kappagoda S, Singh U, Blackburn BG (2011) Antiparasitic therapy. Mayo Clin Proc 86:561–583. https://doi.org/10.4065/mcp.2011.0203
Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B, Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L (2020) Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A 117:26955–26965. https://doi.org/10.1073/pnas.2014441117
Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM (2010) Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob Agents Chemother 54:1186–1192. https://doi.org/10.1128/aac.01269-09
Koehler JW, Smith JM, Ripoll DR, Spik KW, Taylor SL, Badger CV, Grant RJ, Ogg MM, Wallqvist A, Guttieri MC, Garry RF, Schmaljohn CS (2013) A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses. PLoS Negl Trop Dis 7:e2430. https://doi.org/10.1371/journal.pntd.0002430
Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U (2012) A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis 205:1654–1664. https://doi.org/10.1093/infdis/jis273
Kumar N, Sharma NR, Ly H, Parslow TG, Liang Y (2011) Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses. Antimicrob Agents Chemother 55:5553–5559. https://doi.org/10.1128/aac.00725-11
L’Huillier AG, Abed Y, Petty TJ, Cordey S, Thomas Y, Bouhy X, Schibler M, Simon A, Chalandon Y, van Delden C, Zdobnov E, Boquete-Suter P, Boivin G, Kaiser L (2015) E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J Infect Dis 212:1726–1734. https://doi.org/10.1093/infdis/jiv288
Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W (2011) Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 32:1518–1525. https://doi.org/10.1016/j.peptides.2011.05.015
Li F, Lang Y, Ji Z, Xia Z, Han Y, Cheng Y, Liu G, Sun F, Zhao Y, Gao M, Chen Z, Wu Y, Li W, Cao Z (2019) A scorpion venom peptide Ev37 restricts viral late entry by alkalizing acidic organelles. J Biol Chem 294:182–194. https://doi.org/10.1074/jbc.ra118.005015
Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, Ku Z, An Z, Scharton D, Schindewolf C, Menachery VD, Shi PY, Weaver SC (2021) The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv. https://doi.org/10.1101/2021.03.08.434499
Lokhande AS, Devarajan PV (2021) A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19. Eur J Pharmacol 891:173748. https://doi.org/10.1016/j.ejphar.2020.173748
Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:3067. https://doi.org/10.1038/ncomms4067
Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A (2015) Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep 32:29–48. https://doi.org/10.1039/c4np00085d
Mazzon M, Ortega-Prieto AM, Imrie D, Luft C, Hess L, Czieso S, Grove J, Skelton JK, Farleigh L, Bugert JJ, Wright E, Temperton N, Angell R, Oxenford S, Jacobs M, Ketteler R, Dorner M, Marsh M (2019) Identification of broad-spectrum antiviral compounds by targeting viral entry. Viruses 11:176. https://doi.org/10.3390/v11020176
Mercer J, Schelhaas M, Helenius A (2010) Virus entry by endocytosis. Annu Rev Biochem 79:803–833. https://doi.org/10.1146/annurev-biochem-060208-104626
Mokdad AA, Zhu H, Beg MS, Arriaga Y, Dowell JE, Singal AG, Yopp AC (2019) Efficacy and safety of bavituximab in combination with sorafenib in advanced hepatocellular carcinoma: a single-arm, open-label, phase II clinical trial. Target Oncol 14:541–550. https://doi.org/10.1007/s11523-019-00663-3
Monto AS, Fukuda K (2020) Lessons from influenza pandemics of the last 100 years. Clin Infect Dis 70:951–957. https://doi.org/10.1093/cid/ciz803
Moore BR, Page-Sharp M, Stoney JR, Ilett KF, Jago JD, Batty KT (2011) Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother 55:3899–3907. https://doi.org/10.1128/aac.00067-11
Moscona A, Porotto M, Palmer S, Tai C, Aschenbrenner L, Triana-Baltzer G, Li QX, Wurtman D, Niewiesk S, Fang F (2010) A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 202:234–241. https://doi.org/10.1086/653621
Nathan L, Lai AL, Millet JK, Straus MR, Freed JH, Whittaker GR, Daniel S (2020) Calcium ions directly interact with the ebola virus fusion peptide to promote structure-function changes that enhance infection. ACS Infect Dis 6:250–260. https://doi.org/10.1021/acsinfecdis.9b00296
Niyomdecha N, Suptawiwat O, Boonarkart C, Thitithanyanont A, Auewarakul P (2021) Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication. Virus Res 295:198277. https://doi.org/10.1016/j.virusres.2020.198277
O’Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR (2003) Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 47:2518–2525. https://doi.org/10.1128/aac.47.8.2518-2525.2003
Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, Wong G, Wilder-Smith A (2011) Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 11:677–683. https://doi.org/10.1016/s1473-3099(11)70065-2
Pollock S, Nichita NB, Böhmer A, Radulescu C, Dwek RA, Zitzmann N (2010) Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci U S A 107:17176–17181. https://doi.org/10.1073/pnas.1009445107
Puhl AC, Fritch EJ, Lane TR, Tse LV, Yount BL, Sacramento CQ, Fintelman-Rodrigues N, Tavella TA, Maranhão Costa FT, Weston S, Logue J, Frieman M, Premkumar L, Pearce KH, Hurst BL, Andrade CH, Levi JA, Johnson NJ, Kisthardt SC, Scholle F, Souza TML, Moorman NJ, Baric RS, Madrid PB, Ekins S (2021) Repurposing the ebola and marburg virus inhibitors tilorone, quinacrine, and pyronaridine: in vitro activity against SARS-CoV-2 and potential mechanisms. ACS Omega 6:7454–7468. https://doi.org/10.1101/2020.12.01.407361
Rebeaud ME, Zores F (2020) SARS-CoV-2 and the use of chloroquine as an antiviral treatment. Front Med (Lausanne) 7:184. https://doi.org/10.3389/fmed.2020.00184
Rossignol JF (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res 110:94–103. https://doi.org/10.1016/j.antiviral.2014.07.014
Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA (2010) Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 6:e1001110. https://doi.org/10.1371/journal.ppat.1001110
Sample CJ, Hudak KE, Barefoot BE, Koci MD, Wanyonyi MS, Abraham S, Staats HF, Ramsburg EA (2013) A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. Peptides 48:96–105. https://doi.org/10.1016/j.peptides.2013.07.014
Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R (2010) Viral mutation rates. J Virol 84:9733–9748. https://doi.org/10.1128/jvi.00694-10
Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, Glass CA, Wang L, Tor Y, Esko JD (2008) Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A 105:13075–13080. https://doi.org/10.1073/pnas.0805862105
Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117:11727–11734. https://doi.org/10.1073/pnas.2003138117
Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 102:11876–11881. https://doi.org/10.1073/pnas.0505577102
Smith JG, Nemerow GR (2008) Mechanism of adenovirus neutralization by Human alpha-defensins. Cell Host Microbe 3:11–19. https://doi.org/10.1016/j.chom.2007.12.001
Soares MM, King SW, Thorpe PE (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14:1357–1362. https://doi.org/10.1038/nm.1885
Sorin MN, Kuhn J, Stasiak AC, Stehle T (2021) Structural insight into non-enveloped virus binding to glycosaminoglycan receptors: a review. Viruses 13:800. https://doi.org/10.3390/v13050800
St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA, Korshun VA, Tyrrell DL, Schang LM (2010) Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci U S A 107:17339–17344. https://doi.org/10.1073/pnas.1010026107
Straus MR, Tang T, Lai AL, Flegel A, Bidon M, Freed JH, Daniel S, Whittaker GR (2020) Ca(2+) ions promote fusion of middle east respiratory syndrome coronavirus with host cells and increase infectivity. J Virol 94:e00426. https://doi.org/10.1128/jvi.00426-20
Tandon R, Sharp JS, Zhang F, Pomin VH, Ashpole NM, Mitra D, Jin W, Liu H, Sharma P, Linhardt RJ (2020) Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. bioRxiv. https://doi.org/10.1101/2020.06.08.140236
Tang JW, Lam TT, Zaraket H, Lipkin WI, Drews SJ, Hatchette TF, Heraud JM, Koopmans MP (2017) Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance. Lancet Infect Dis 17:e320–e326. https://doi.org/10.1016/s1473-3099(17)30238-4
Tang T, Jaimes JA, Bidon MK, Straus MR, Daniel S, Whittaker GR (2021) Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin. ACS Infect Dis 7:264–272. https://doi.org/10.1021/acsinfecdis.0c00701
Triggle CR, Bansal D, Ding H, Islam MM, Farag E, Hadi HA, Sultan AA (2021) A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Front Immunol 12:631139. https://doi.org/10.3389/fimmu.2021.631139
Tripathi S, Tecle T, Verma A, Crouch E, White M, Hartshorn KL (2013) The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J Gen Virol 94:40–49. https://doi.org/10.1099/vir.0.045013-0
Vandini S, Biagi C, Fischer M, Lanari M (2019) Impact of rhinovirus infections in children. Viruses 11:521. https://doi.org/10.3390/v11060521
Vigant F, Lee J, Hollmann A, Tanner LB, Akyol Ataman Z, Yun T, Shui G, Aguilar HC, Zhang D, Meriwether D, Roman-Sosa G, Robinson LR, Juelich TL, Buczkowski H, Chou S, Castanho MA, Wolf MC, Smith JK, Banyard A, Kielian M, Reddy S, Wenk MR, Selke M, Santos NC, Freiberg AN, Jung ME, Lee B (2013) A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 9:e1003297. https://doi.org/10.1371/journal.ppat.1003297
Vigant F, Santos NC, Lee B (2015) Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol 13:426–437. https://doi.org/10.1038/nrmicro3475
Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G, Li Y, Meng G, Wang W, Shi W, Zhong W, Jiang S, Liu K (2018) De novo design of α-helical lipopeptides targeting viral fusion proteins: a promising strategy for relatively broad-spectrum antiviral drug discovery. J Med Chem 61:8734–8745. https://doi.org/10.1021/acs.jmedchem.8b00890
Wang C, Wang S, Li D, Wei DQ, Zhao J, Wang J (2020a) Human intestinal defensin 5 inhibits SARS-CoV-2 invasion by cloaking ACE2. Gastroenterology 159:1145–1147.e1144. https://doi.org/10.1053/j.gastro.2020.05.015
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z, Zhong W, Wang M (2020b) The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6:28. https://doi.org/10.1038/s41421-020-0169-8
Weisz OA (2003) Acidification and protein traffic. Int Rev Cytol 226:259–319. https://doi.org/10.1016/s0074-7696(03)01005-2
Widjaja I, Wang C, van Haperen R, Gutiérrez-Álvarez J, van Dieren B, Okba NMA, Raj VS, Li W, Fernandez-Delgado R, Grosveld F, van Kuppeveld FJM, Haagmans BL, Enjuanes L, Drabek D, Bosch BJ (2019) Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect 8:516–530. https://doi.org/10.1080/22221751.2019.1597644
Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B (2010) A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 107:3157–3162. https://doi.org/10.1073/pnas.0909587107
Woolhouse M, Scott F, Hudson Z, Howey R, Chase-Topping M (2012) Human viruses: discovery and emergence. Philos Trans R Soc Lond Ser B Biol Sci 367:2864–2871. https://doi.org/10.1098/rstb.2011.0354
Wu Y, Boulogne C, Carle S, Podinovskaia M, Barth H, Spang A, Cintrat JC, Gillet D, Barbier J (2020) Regulation of endo-lysosomal pathway and autophagic flux by broad-spectrum antipathogen inhibitor ABMA. FEBS J 287:3184–3199. https://doi.org/10.1111/febs.15201
Xu J, Shi PY, Li H, Zhou J (2020) Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 6:909–915. https://doi.org/10.1021/acsinfecdis.0c00052
Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23:300–302. https://doi.org/10.1038/cr.2012.165
Zenilman JM, Fuchs EJ, Hendrix CW, Radebaugh C, Jurao R, Nayak SU, Hamilton RG, McLeod Griffiss J (2015) Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antivir Res 123:114–119. https://doi.org/10.1016/j.antiviral.2015.09.008
Zhang J, Mulvenon A, Makarov E, Wagoner J, Knibbe J, Kim JO, Osna N, Bronich TK, Poluektova LY (2013) Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection. Biomaterials 34:3846–3857. https://doi.org/10.1016/j.biomaterials.2013.01.026
Zhang Y, Xia L, Yuan Y, Li Q, Han L, Yang G, Hu H (2020) Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res 289:198167. https://doi.org/10.1016/j.virusres.2020.198167
Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, Chan CC, Leung HC, Fai N, Lin YP, Zhang AJ, Jin DY, Yuen KY, Zheng BJ (2016) A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep 6:22008. https://doi.org/10.1038/srep22008
Zhao H, To KKW, Chu H, Ding Q, Zhao X, Li C, Shuai H, Yuan S, Zhou J, Kok KH, Jiang S, Yuen KY (2018) Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. Nat Commun 9:2358. https://doi.org/10.1038/s41467-018-04792-7
Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY (2020) A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. Nat Commun 11:4252. https://doi.org/10.1038/s41467-020-17986-9
Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY (2021) Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun 12:1517. https://doi.org/10.1038/s41467-021-21825-w
Zhou Y, Simmons G (2012) Development of novel entry inhibitors targeting emerging viruses. Expert Rev Anti-Infect Ther 10:1129–1138. https://doi.org/10.1586/eri.12.104
Zumla A, Hui DS, Perlman S (2015) Middle East respiratory syndrome. Lancet 386:995–1007. https://doi.org/10.1016/s0140-6736(15)60454-8
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Zhao, H., Yuen, KY. (2022). Broad-spectrum Respiratory Virus Entry Inhibitors. In: Jiang, S., Lu, L. (eds) Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, vol 1366. Springer, Singapore. https://doi.org/10.1007/978-981-16-8702-0_9
Download citation
DOI: https://doi.org/10.1007/978-981-16-8702-0_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-8701-3
Online ISBN: 978-981-16-8702-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)